Every claim on this site traces back to published literature. This page is that trail — organized by mechanism, not by product, with the landmark study behind each cluster.

This index reflects published research literature and is provided for research and educational reference only. It is not a claim that any compound sold by Agape Compounds treats, cures, or prevents any condition. Several compounds referenced below are FDA-approved medications or investigational drugs, cited here as scientific literature — not as products we sell.

1. Gastric & Tissue Regeneration Factors — BPC-157
Chang, C.-H., et al. (2011). Journal of Applied Physiology, 110(3), 774–780. · Seiwerth, S., et al. (2021). Frontiers in Pharmacology, 12, 627533. · Sikiric, P., et al. (2003). Inflammopharmacology, 11(5), 455–467.

2. ECM & Genomic Modulators — GHK-Cu, Ac-SDKP
Pickart, L., et al. (2015). BioMed Research International, 2015, 1–7. · Peng, H., et al. (2003). Hypertension, 42(6), 1164–1170.

3. G-Actin Sequestration & Cell Migration — TB-500 / Thymosin β4
Nguyen, M. T., et al. (2023). Cells, 12(21), 2523. · Sosne, G., et al. (2015). Expert Opinion on Biological Therapy, 15(sup1), S123–S128. · Philp, D., et al. (2003). Mechanisms of Ageing and Development, 124(1), 125–129.

4. Epithelial Growth & Mucosal Barrier — KGF/KGF-2 (Palifermin)
Spielberger, R., et al. (2004). NEJM, 351(25), 2590–2598. · Finch, P. W., & Rubin, J. S. (2004). Journal of Facial Plastic Surgery, 6(1), 21–28.

5. Host Defense & Neurovascular Signaling — LL-37, KPV, Substance P, Thymosin α-1
Grönberg, A., et al. (2014). Wound Repair and Regeneration, 22(5), 613–621. · Yamada, M., et al. (2008). Cornea, 27, S24–S30.

6. Integrin-Binding & Microvascular Mimetics — QK, RGD-Motif, SIKVAV/IKVAV
D’Andrea, L. D., et al. (2005). PNAS, 102(40), 14215–14220. · Silva, G. A., et al. (2004). Science, 303(5662), 1357–1361.

7. Gap-Junction & Growth Factor Therapeutics — αCT1, TP508, Becaplermin
Ghatnekar, G. S., et al. (2015). Regenerative Medicine, 10(1), 11–23. · Smiell, J. M., et al. (1999). Wound Repair and Regeneration, 7(5), 335–346.

8. Myostatin Blocks & Somatotropic Secretagogues — ACE-031, Follistatin, CJC-1295, Sermorelin, Tesamorelin, Ipamorelin, GHRP-2/6, Hexarelin
Attie, K. M., et al. (2013). Muscle & Nerve, 47(3), 416–423. · Falutz, J., et al. (2010). JAMA, 303(21), 2141–2148. · Teichman, S. L., et al. (2006). JCEM, 91(3), 799–805.

9. Splice Variants & Insulin-Like Growth Dynamics — IGF-1, IGF-1 LR3, IGF-1 DES(1-3), MGF, PEG-MGF
Goldspink, G. (2005). General and Comparative Endocrinology, 142(1-2), 44–48. · Tomas, F. M., et al. (1993). Journal of Endocrinology, 137(3), 413–421.

10. Mitochondrial Respiration & Metabolic Switch Agents — MOTS-c, SS-31, 5-Amino-1MQ, Humanin, BAIBA, Epitalon
Lee, C., et al. (2015). Cell Metabolism, 21(3), 443–454. · Szeto, H. H. (2014). Future Medicinal Chemistry, 6(12), 1363–1381. · Neelakantan, H., et al. (2018). Biochemical Pharmacology, 147, 141–152.
Regulatory note: SS-31 (elamipretide) is FDA-approved (Forzinity, September 2025) for Barth syndrome. Cited here as literature only — not sold by Agape Compounds as a research compound.

11. Longevity, Sarcopenia & Myokine Rescues — α-Klotho, Osteocalcin, Irisin, Apelin, FOXO4-DRI
Baar, M. P., et al. (2017). Cell, 169(1), 132–147. · Boström, P., et al. (2012). Nature, 481(7382), 463–468. · Vinel, C., et al. (2018). Nature Medicine, 24(12), 1860–1871.

12. Metabolic & Incretin Receptor Agonists — Retatrutide, Tirzepatide, Semaglutide, Survodutide, Cagrilintide, Liraglutide
Jastreboff, A. M., et al. (2023). NEJM, 389(6), 514–526. · Jastreboff, A. M., et al. (2022). NEJM, 387(3), 205–216. · Wilding, J. P. H., et al. (2021). NEJM, 384(11), 989–1002.
Regulatory note: every compound in this cluster is either FDA-approved (tirzepatide, semaglutide, liraglutide) or an investigational new drug (retatrutide, survodutide, cagrilintide). None are sold by Agape Compounds as research-use products; cited as clinical literature only.

13. Cognitive & Neurotrophic Peptides — Semax, Selank, Dihexa, Cerebrolysin, DSIP
Dolotov, O. V., et al. (2006). Brain Research, 1117(1), 54–60. · McCoy, A. T., et al. (2013). J Pharmacol Exp Ther, 344(1), 141–154. · Muresanu, D. F., et al. (2016). Stroke, 47(1), 151–159.

14. Immune & Thymic Peptides — Thymosin Alpha-1, Thymalin, Thymogen
King, R., & Tuthill, C. (2016). Vitamins and Hormones, 102, 151–178.

15. Longevity & Bioregulator Peptides — Epitalon, Pinealon, Vilon, Vesugen
Khavinson, V. Kh., et al. (2003). Bulletin of Experimental Biology and Medicine, 135(6), 590–592.

16. Melanocortin & Sexual-Health Peptides — Bremelanotide (PT-141), Melanotan I, Melanotan II
Kingsberg, S. A., et al. (2019). Obstetrics & Gynecology, 134(5), 899–908.
Regulatory note: bremelanotide (Vyleesi) and Melanotan I (afamelanotide/Scenesse) are both FDA-approved medications for specific narrow indications. Cited here as literature only.